VTRS Viatris Inc
Pharmaceutical Preparations · Nasdaq · SEC CIK 1792044 · Fiscal year ends 12/31
Financial factors as of 2026-09-30 (2026Q3), TTM = sum of the last four quarters
Growth
TTM revenue YoY4.3%
TTM net income YoY—
TTM EPS YoY83.1%
Revenue 3-yr CAGR-1.6%
Net income 3-yr CAGR—
Margins
Gross margin35.3%
Operating margin-0.0%
Net margin—
FCF margin14.3%
EBITDA margin19.1%
Returns
ROE—
ROA—
ROIC (approx.)-0.0%
Asset turnover0.41x
Leverage & solvency
Liabilities / assets60.5%
Debt / equity0.97x
Current ratio1.55x
Interest coverage-0.01x
Cash quality & payout
Operating cash flow / net income—
Accruals ratio—
Payout ratio—
Capex / revenue2.5%
Factor history charts and full statement history on Pro 🔒
Financial statements
| Line item | FY2025*2025-12-31 | FY2024*2024-12-31 | FY2023*2023-12-31 | FY2022*2022-12-31 | FY2021*2021-12-31 |
|---|---|---|---|---|---|
| Income statement | |||||
| Revenue | $14.30B | $14.74B | $15.43B | $16.26B | $17.89B |
| Cost of revenue | $9.29B | $9.12B | $8.99B | $9.77B | $12.31B |
| Gross profit | $5.01B | $5.62B | $6.44B | $6.50B | $5.58B |
| R&D expense | $965.90M | $808.70M | $805.20M | $662.20M | $681.00M |
| SG&A expense | $3.79B | $4.10B | $4.07B | $4.18B | $4.53B |
| Operating income | -$2.66B | $10.10M | $766.20M | $1.61B | -$34.00M |
| Interest expense | $471.30M | $550.00M | $573.10M | $592.40M | $636.20M |
| Pretax income | -$3.67B | -$623.20M | $202.90M | $2.81B | -$664.40M |
| Income tax | -$150.10M | $11.00M | $148.20M | $734.60M | $604.70M |
| Net income | -$3.51B | -$634.20M | $54.70M | $2.08B | -$1.27B |
| EBITDA | $135.20M | $2.90B | $3.51B | $4.64B | $4.47B |
| EPS (basic) | -3.00 | -0.53 | 0.05 | 1.71 | -1.05 |
| EPS (diluted) | -3.00 | -0.53 | 0.05 | 1.71 | -1.05 |
| Dividends declared per share | 0.48 | 0.48 | 0.48 | 0.48 | 0.33 |
| Weighted avg. shares (diluted) | — | — | 1.21B | 1.22B | 1.21B |
| Balance sheet | |||||
| Cash & equivalents | $1.32B | $736.10M | $991.90M | $1.26B | $706.20M |
| Short-term investments | $40.70M | $38.00M | $37.00M | $35.30M | $38.20M |
| Receivables | $3.03B | $3.22B | $3.70B | $3.81B | $4.27B |
| Inventory | $4.00B | $3.85B | $3.47B | $3.52B | $3.98B |
| Current assets | $9.79B | $9.52B | $12.98B | $10.64B | $10.90B |
| PP&E, net | $2.61B | $2.67B | $2.76B | $3.02B | $3.19B |
| Goodwill | $6.75B | $9.13B | $9.87B | $10.43B | $12.11B |
| Intangibles | $15.10B | $17.07B | $19.18B | $22.61B | $26.13B |
| Total assets | $37.19B | $41.50B | $47.69B | $50.02B | $54.84B |
| Current liabilities | $7.09B | $5.78B | $7.78B | $6.75B | $9.88B |
| Short-term debt | $1.93B | $600,000 | $1.93B | $1.25B | $1.86B |
| Long-term debt | $12.48B | $14.04B | $16.19B | $18.02B | $19.72B |
| Total debt | $14.41B | $14.04B | $18.12B | $19.27B | $21.58B |
| Total liabilities | $22.48B | $22.87B | $27.22B | $28.95B | $34.35B |
| Shareholders' equity | $14.71B | $18.64B | $20.47B | $21.07B | $20.49B |
| Net debt | $13.09B | $13.30B | $17.13B | $18.00B | $20.87B |
| Cash flow statement | |||||
| Operating cash flow | $2.32B | $2.30B | $2.90B | $3.00B | $3.02B |
| Capital expenditure | $378.80M | $326.00M | $377.00M | $406.00M | $457.20M |
| Free cash flow | $1.94B | $1.98B | $2.52B | $2.59B | $2.56B |
| Investing cash flow | -$427.70M | $1.80B | -$864.50M | $1.47B | -$117.80M |
| Financing cash flow | -$1.29B | -$4.33B | -$2.30B | -$3.88B | -$3.01B |
| Depreciation & amortization | $2.80B | $2.89B | $2.74B | $3.03B | $4.51B |
| Stock-based compensation | $177.70M | $146.10M | $180.70M | $116.40M | $111.20M |
| Share buybacks | $500.50M | $250.00M | $250.00M | $0 | $0 |
Free plan shows the latest 5 periods; Pro shows all 8 🔒
· No price-based ratios such as P/E or P/B (the site uses no licensed market data). Blanks are shown as —.
Source: SEC EDGAR XBRL (financial statements filed with the SEC), updated 2026-11-18 06:30.